Market Risk

Showing 3023 articles
Business

Bausch Health's Deep Discount: Market Overshoot or Justified Skepticism?

With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.

Business

Almirall's Valuation Puzzle: Undervalued Gem or Market Mirage?

Shares of Spanish dermatology specialist Almirall (BME:ALM) present a conundrum for investors. While recent trading has been volatile, a key valuation model suggests the stock is trading at a 7.8% discount to its estimated fair value. We examine the bullish case built on its pipeline, the risks it faces, and what the significant gap between its current and forward P/E ratios might signal.

Business

EQT Diversifies with Secondaries Push and Critical Minerals Research as Market Questions Valuation

Swedish investment giant EQT is expanding its footprint through a strategic partnership in the private equity secondaries market with Coller Capital, while its foundation launches a science grant program targeting substitutes for critical minerals. The dual moves signal a broader strategy to tap into new fee streams and align with long-term sustainability trends, even as the firm's shares trade at levels some analysts consider undervalued.